Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multi-drug Resistance in Human Glioblastoma Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Current treatment of glioblastoma after surgery consists of a combination of fractionated radiotherapy and temozolomide. However, it is difficult to completely remove glioblastoma because it has uncertain boundaries with surrounding tissues. Moreover, combination therapy is not always successful because glioblastoma has diverse resistances. To overcome these limitations, we examined the combined effects of chemotherapy and knockdown of mitogen-activated protein kinase phosphatase-1 (MKP-1). Materials and Methods We used ten different anti-cancer drugs (cisplatin, cyclophosphoamide, doxorubicin, epirubicin,etoposide, 5-fluorouracil, gemcitabine, irinotecan, mitomycin C, and vincristine) to treat glioblastoma multiforme (GBM) cells. Knockdown of MKP-1 was performed using siRNA and lipofectamine. The basal level of MKP-1 in GBM was analyzed based on cDNA microarray data obtained from the Gene Expression Omnibus (GEO) databases. Results Anti-cancer drug-induced cell death was significantly enhanced by knockdown of MKP-1, and this effect was most prominent in cells treated with irinotecan and etoposide. Treatment with these two drugs led to significantly increased phosphorylation of c-Jun N-terminal kinase (JNK)in a time-dependent manner, while pharmacological inhibition of JNK partially inhibited druginduced cell death. Knockdown of MKP-1 also enhanced drug-induced phosphorylation of JNK. Conclusion Increased MKP-1 expression levels could be the cause of the high resistance to conventional chemotherapeutics in human GBM. Therefore, MKP-1 is an attractive target for overcoming drug resistance in this highly refractory malignancy.
Abstract
Purpose Current treatment of glioblastoma after surgery consists of a combination of fractionated radiotherapy and temozolomide. However, it is difficult to completely remove glioblastoma because it has uncertain boundaries with surrounding tissues. Moreover, combination therapy is not always successful because glioblastoma has diverse resistances. To overcome these limitations, we examined the combined effects of chemotherapy and knockdown of mitogen-activated protein kinase phosphatase-1 (MKP-1). Materials and Methods We used ten different anti-cancer drugs (cisplatin, cyclophosphoamide, doxorubicin, epirubicin,etoposide, 5-fluorouracil, gemcitabine, irinotecan, mitomycin C, and vincristine) to treat glioblastoma multiforme (GBM) cells. Knockdown of MKP-1 was performed using siRNA and lipofectamine. The basal level of MKP-1 in GBM was analyzed based on cDNA microarray data obtained from the Gene Expression Omnibus (GEO) databases. Results Anti-cancer drug-induced cell death was significantly enhanced by knockdown of MKP-1, and this effect was most prominent in cells treated with irinotecan and etoposide. Treatment with these two drugs led to significantly increased phosphorylation of c-Jun N-terminal kinase (JNK)in a time-dependent manner, while pharmacological inhibition of JNK partially inhibited druginduced cell death. Knockdown of MKP-1 also enhanced drug-induced phosphorylation of JNK. Conclusion Increased MKP-1 expression levels could be the cause of the high resistance to conventional chemotherapeutics in human GBM. Therefore, MKP-1 is an attractive target for overcoming drug resistance in this highly refractory malignancy.
참고문헌 (22)
- Wen PY, "Malignant gliomas in adults", N Engl J Med, 359, pp.492~507 (2008)
- Meyer MA, "Malignant gliomas in adults", N Engl J Med, 359, pp.1850~ (2008)
- Krakstad C, "Survival signalling and apoptosis resistance in glioblastomas : opportunities for targeted therapeutics", Mol Cancer, 9, pp.135~ (2010)
- Reijneveld JC, "Angiogenesis in malignant primary and metastatic brain tumors", J Neurol, 247, pp.597~608 (2000)
- Bredel M, "Brain-tumour drug resistance: the bare essentials", Lancet Oncol, 3, pp.397~406 (2002)
- Wick W, "Pathway inhibition : emerging molecular targets for treating glioblastoma", Neuro Oncol, 13, pp.566~579 (2011)
- Riemenschneider MJ, "MGMT promoter methylation in malignant gliomas", Target Oncol, 5, pp.161~165 (2010)
- Bredel M, "Anticancer drug resistance in primary human brain tumors", Brain Res Brain Res Rev, 35, pp.161~204 (2001)
- Patterson KI, "Dual-specificity phosphatases : critical regulators with diverse cellular targets", Biochem J, 418, pp.475~489 (2009)
- Bermudez O, "The dual-specificity MAP kinase phosphatases: critical roles in development and cancer", Am J Physiol Cell Physiol, 299, pp.C189~C202 (2010)
- Keyse SM, "Dual-specificity MAP kinase phosphatases(MKPs)and cancer", Cancer Metastasis Rev, 27, pp.253~261 (2008)
- Small GW, "Repression of mitogenactivated protein kinase(MAPK)phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44", 42-MAPK, 2003, pp.307, 861~869
- Small GW, "Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role", Mol Pharmacol, 66, pp.1478~1490 (2004)
- Wang J, "ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells", Cancer Res, 67, pp.11933~11941 (2007)
- Loda M, "Expression of mitogenactivated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis", Am J Pathol, 149, pp.1553~1564 (1996)
- Haigis KM, "Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon", Nat Genet, 40, pp.600~608 (2008)
- Szakacs G, "Targeting multidrug resistance in cancer", Nat Rev Drug Discov, 5, pp.219~234 (2006)
- Wang Z, "Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance", Cancer Res, 66, pp.8870~8877 (2006)
- Small GW, "Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance", Cancer Res, 67, pp.4459~4466 (2007)
- Chamberlain MC, "Bevacizumab for the treatment of recurrent glioblastoma", Clin Med Insights Oncol, 5, pp.117~129 (2011)
- Jakobsen JN, "Irinotecan and bevacizumab in recurrent glioblastoma multiforme", Expert Opin Pharmacother, 12, pp.825~833 (2011)
- Watanabe K, "Combination chemotherapy using carboplatin(JM-8)and etoposide(JET therapy)for recurrent malignant gliomas : a phase II study", Acta Neurochir(Wien), 144, pp.1265~1270 (2002)